Acrivon Therapeutics, Inc. ACRV
1.57 USD -0.01 (-0.63%)
At closeNov 10, 2026, 5:17 PM EST
1.65 +0.08 +5.10%
After hours · Nov 10, 5:17 PM ET
1.55 Day range 1.65
1.29 52-week range 3.01
- YTD
- -34.85%
- 1 year
- -22.66%
News
seekingalpha.com Acrivon Therapeutics, Inc. (ACRV) Discusses ACR-525 Acquisition and PKC Inhibitor Preclinical Program Transcript Acrivon Therapeutics, Inc. (ACRV) Discusses ACR-525 Acquisition and PKC Inhibitor Preclinical Program Transcript
benzinga.com Acrivon Therapeutics Acquires Janus Kinase 1 Inhibitor ACR-525 From Aqilion AB; Terms Undisclosed Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary…
globenewswire.com Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB Asset acquisition establishes immunology and inflammation (I&I) as a strategic pillar alongside oncology, extending the company into autoimmune disease
globenewswire.com Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics WATERTOWN, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing…
benzinga.com Acrivon Therapeutics To Present Dose Escalation Data From Its Current Phase 1/2 Trial Of ACR-2316 At 38th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical-stage biotechnology company discovering and developing precision medicines utilizing its proprietary…
globenewswire.com Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium Timothy A. Yap, MBBS, Ph.D., FRCP, of The University of Texas MD Anderson Cancer Center to present results from the dose escalation phase of the ACR-2316 Phase 1/2 trial on November 20, 2026 Durable…
benzinga.com Acrivon Therapeutics Advances ACR-7280, Showing Complete Tumor Regression In AML Models, With IND Filing Targeted For H1 2027 ACR-7280 demonstrated complete tumor regression in aggressive AML xenograft modelsPrioritized among multiple AP3-discovered, highly selective CDK11 inhibitor candidates based on potent single agent…
globenewswire.com Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027 ACR-7280 demonstrated complete tumor regression in aggressive AML xenograft models Prioritized among multiple AP3-discovered, highly selective CDK11 inhibitor candidates based on potent single agent…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 13.3% to $0.55 during Wednesday's after-market session. Impact BioMedical (AMEX:IBO) stock rose 10.77% to $3.77. The company's market cap…
zacks.com What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy? Acrivon Therapeutics, Inc. (ACRV) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ACRV's 50-day simple moving average…
globenewswire.com Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing…
globenewswire.com Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer Experienced biotechnology executive brings an extensive track record in business development, strategic transactions, licensing and corporate strategy Experienced biotechnology executive brings an…
zacks.com Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy Does Acrivon Therapeutics, Inc. (ACRV) have what it takes to be a top stock pick for momentum investors? Let's find out.- benzinga.com Acrivon Therapeutics Q2 EPS $(0.43) Beats $(0.50) Estimate Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.50) by 14 percent. This is a 21.82 percent increase over losses of…
globenewswire.com Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026
benzinga.com Acrivon Therapeutics Says ACR-2316 Advances Into Randomized Dose Expansion Portion Of Its Ongoing Phase 1/2 Study Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a yearOral weekly…
globenewswire.com Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a year Oral weekly…
benzinga.com Acrivon Therapeutics To Highlight AP3 Platform For Pathway-Based Drug Discovery And Development At AACR D3 July 21-24 Presentations and DetailsOral Podium PresentationTitle: Acrivon Predictive Precision Proteomics (AP3): Next Generation Precision Medicine for Phosphoproteomics-Guided Drug DiscoveryPresenter: Lei…
globenewswire.com Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference Presentations feature mechanistic data on ACR-2316, a potential first-in-class, clinical WEE1/PKMYT1 inhibitor, rationally designed with AP3 for potent single agent activity and superior therapeutic…
seekingalpha.com Acrivon Therapeutics: Priced For Failure, Built For Precision Acrivon Therapeutics (ACRV) trades below cash value, with the market deeply discounting its platform and pipeline despite promising early data. ACRV's AP3 platform enables precision patient-matching…
globenewswire.com Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit WATERTOWN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing…
globenewswire.com Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WATERTOWN, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing…- benzinga.com Acrivon Therapeutics Q1 EPS $(0.49) Beats $(0.53) Estimate Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.53) by 7.55 percent. This is a 3.92 percent increase over losses of…
globenewswire.com Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer (biopsy-independent) serous endometrial cancer arms…
benzinga.com Acrivon Therapeutics Presents Preclinical Data On Three Posters At AACR 2026 Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary…
globenewswire.com Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or ACR-2316 with anti-PD-L1 and strong synergy of ACR-368 with Topoisomerase 1 (Topo 1) inhibition
globenewswire.com Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WATERTOWN, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing…
defenseworld.net Acrivon Therapeutics (NASDAQ:ACRV) Trading Up 3.2% – Still a Buy? Shares of Acrivon Therapeutics, Inc. (NASDAQ: ACRV - Get Free Report) were up 3.2% on Monday. The stock traded as high as $1.64 and last traded at $1.61. Approximately 865,467 shares traded hands…
defenseworld.net Financial Survey: Oasmia Pharmaceutical (OTCMKTS:OASMY) versus Acrivon Therapeutics (NASDAQ:ACRV) Acrivon Therapeutics (NASDAQ: ACRV - Get Free Report) and Oasmia Pharmaceutical (OTCMKTS:OASMY - Get Free Report) are both small-cap medical companies, but which is the better investment? We will…
benzinga.com Acrivon Therapeutics Q4 EPS $(0.49) Beats $(0.57) Estimate Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.57) by 13.58 percent. This is a 18.33 percent increase over losses…- benzinga.com Acrivon Therapeutics To Reveal Pre-Clinical AP3 Data At The 2026 AACR Annual Meeting ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates…
benzinga.com Piper Sandler Maintains Overweight on Acrivon Therapeutics, Raises Price Target to $8 Piper Sandler analyst Edward Tenthoff maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Overweight and raises the price target from $6 to $8.
benzinga.com Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls Acrivon Therapeutics shares new trial data showing strong cancer responses, early tumor shrinkage, and pipeline progress, while confirming cash runway into 2027.
benzinga.com Dow Jumps Over 250 Points; US Initial Jobless Claims Increase 
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings - benzinga.com Market-Moving News for January 8th ACON: 54% | Aclarion Reports Triple-Digit Growth for AI Back Pain Platform as Nociscan Adoption Accelerates ACRV: 38% | Acrivon Therapeutics Announces Update On ACR-368 Program, Reports Initial…
- benzinga.com Acrivon Therapeutics Announces Update On ACR-368 Program, Reports Initial Clinical Data From ACR-2316 Phase 1 Trial, Nominates Next AP3-Enabled Preclinical Development Candidate ACR-6840 Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Acrivon Therapeutics to Release New Cancer Drug Data on Jan. 8 Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Acrivon Therapeutics Said It Will Be Providing ACR-368 and ACR-2316 Clinical Data And Other Updates In January 2026 Topics will include:Updated interim ACR-368 clinical data from the ongoing registrational-intent Phase 2b study as well as an update on the additional recently initiated tumor biopsy-independent…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $19 Price Target HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and maintains $19 price target.
- benzinga.com Acrivon Therapeutics Q3 EPS $(0.47) Beats $(0.61) Estimate Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.61) by 22.57 percent. This is a 20.34 percent increase over losses…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Acrivon Therapeutics To Deliver Three Presentations At The AACR-NCI-EORTC Highlighting Advances From Its Proprietary Generative Phosphoproteomics AP3 Platform For Developing Precision Medicines AP3 Generative AI KaiSR model globally assesses drug effects on the entire intracellular protein signaling network for optimal drug design and precision medicine developmentFavorable ACR-2316…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session